Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Ford Investor Services, Inc.
$12.00
Provider: Reuters Investment Profile
$20.00
Provider: Zacks Investment Research Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Fate Therapeutics Inc announces observed effects of pharmacologic modulation on T cell compartment from phase 1b study of PROHEMA


Wednesday, 26 Feb 2014 07:03am EST 

Fate Therapeutics Inc:Release of new data on observed effects of ex vivo pharmacologic modulation on CD8+ T cells and immune reconstitution from its previously-completed Phase 1b clinical trial of PROHEMA in adult patients undergoing hematopoietic stem cell (HSC) transplantation for hematologic malignancy.Researchers affiliated with Harvard Medical School performed an analysis of the CD8+ T cell compartment using patient samples from the ProHema-01 trial.Says At Day 100, subjects who received PROHEMA and an unmanipulated cord blood unit (n=12) showed a two-fold increase in the percentage of naïve and early memory T cell fraction within the CD8+ T cell compartment as compared to subjects who received two unmanipulated cord blood units (n=9).Says these naïve and early memory CD8+ T cell populations are believed to play a key role in promoting immune reconstitution and viral immunity following cord blood transplantation.Following an optimization of the PROHEMAmanufacturing process, the company expects to resume enrollment of its Phase 2 clinical trial in the first half of 2014, with the goal of generating full data on the primary and secondary endpoints related to engraftment in mid-2015. 

Company Quote

6.28
-0.17 -2.64%
25 Jul 2014